Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Investment Securities (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Gains from Investment Securities for 10 consecutive years, with -$223.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 648.02% year-over-year to -$223.3 million, compared with a TTM value of $39.5 million through Dec 2025, down 3.82%, and an annual FY2025 reading of -$451000.0, down 101.1% over the prior year.
  • Gains from Investment Securities was -$223.3 million for Q4 2025 at Zevra Therapeutics, down from $221.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $221.7 million in Q3 2025 and bottomed at -$223.3 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $3.2 million, with a median of $61000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities tumbled 17290.16% in 2022, then skyrocketed 76351.03% in 2025.
  • Year by year, Gains from Investment Securities stood at -$66000.0 in 2021, then soared by 3821.83% to $2.5 million in 2022, then plummeted by 103.58% to -$88000.0 in 2023, then skyrocketed by 46397.73% to $40.7 million in 2024, then plummeted by 648.02% to -$223.3 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ZVRA at -$223.3 million in Q4 2025, $221.7 million in Q3 2025, and $40.7 million in Q4 2024.